Clinical Trials Directory

Trials / Completed

CompletedNCT04889677

Study of a Single Dose of Danicopan in Healthy Participants

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of ACH 0144471 In Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Alexion Pharmaceuticals, Inc. · Industry
Sex
All
Age
21 Years – 55 Years
Healthy volunteers
Accepted

Summary

This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants. Four different doses (200 milligrams \[mg\], 600 mg, 1200 mg, 2400 mg) and dose-matched placebo were administered under fasted and fed conditions.

Conditions

Interventions

TypeNameDescription
DRUGDanicopan
DRUGPlacebo

Timeline

Start date
2016-02-04
Primary completion
2016-06-21
Completion
2016-06-21
First posted
2021-05-17
Last updated
2021-05-17

Locations

1 site across 1 country: New Zealand

Source: ClinicalTrials.gov record NCT04889677. Inclusion in this directory is not an endorsement.

Study of a Single Dose of Danicopan in Healthy Participants (NCT04889677) · Clinical Trials Directory